作者
Sonal Singh, Yoon K Loke, Curt D Furberg
发表日期
2008/9/24
期刊
JAMA: the journal of the American Medical Association
卷号
300
期号
12
页码范围
1439
出版商
American Medical Association
简介
Context
Inhaled anticholinergics (ipratropium bromide or tiotropium bromide) are widely used in patients with chronic obstructive pulmonary disease (COPD) but their effect on the risk of cardiovascular outcomes is unknown.
Objective
To ascertain the cardiovascular risks of inhaled anticholinergics, including cardiovascular death, myocardial infarction (MI), and stroke.
Data Sources
Systematic searches were conducted on March 19, 2008, of relevant articles in MEDLINE, the Cochrane Database of systematic reviews, regulatory authority Web sites in the United States and the United Kingdom, and manufacturers' trial registries with no date restrictions.
Study Selection
Randomized controlled trials of any inhaled anticholinergic for treatment of COPD that had at least 30 days of treatment and reported on cardiovascular events.
Data Extraction
The primary outcome was a composite of cardiovascular death, MI, or stroke. The …
引用总数
学术搜索中的文章
S Singh, YK Loke, CD Furberg - Jama, 2008
S Singh, YK Loke, CD Furberg - JAMA-JOURNAL OF THE AMERICAN MEDICAL …, 2009